LAMEA Syphilis Testing Market Size, Share & Forecast, 2028

LAMEA Syphilis Testing Market Size, Share & Industry Trends Analysis Report By Type, By Location of Testing (Laboratory testing and Point of care (POC) testing), By Country and Growth Forecast, 2022 - 2028

Published Date: May-2022 | Number of Pages: 69 | Format: PDF | Report ID: KBV-18433

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


COVID-19

Get in-depth analysis of the COVID-19 impact on the LAMEA Syphilis Testing Market

Market Report Description

The Latin America, Middle East and Africa Syphilis Testing Market would witness market growth of 8.4% CAGR during the forecast period (2022-2028).

Three to four weeks after contracting the germs, a person would experience the main phase of syphilis. One or more open sores called chancres, which are generally firm and painless, and swollen lymph nodes are indications of primary infection. Neck stiffness, headaches, hearing loss, trouble with reflexes, and paralysis are all indications of secondary infection. Untreated syphilis develops to the tertiary stage, resulting in recurrent lesions and progressively severe symptoms including catastrophic multi-organ infections, cardiovascular and neurologic damage.

Congenital syphilis occurs when a syphilis-infected woman transmits the infection to her unborn child during pregnancy, which can result in stillbirth or death soon after birth, miscarriage, preterm, malformed bones, and brain and nerve disorders in the newborn. Rapid plasma reagin (RPR), a syphilis blood test that checks for antibodies against the syphilis bacterium, is one of the tests used to diagnose syphilis infection. Antibodies are proteins that the immune system produces to combat invading things such as germs. Antibodies to syphilis are also checked by the Venereal Disease Research Laboratory (VDRL).

Sexually transmitted infections (STDs) are major public health issues that frequently result in serious complications and consequences, such as infertility. Infection with STDs makes HIV transmission easier, hence early detection and treatment of STDs as part of other therapies is one of the most cost-effective ways to prevent HIV transmission. STDs or sexually transmitted infections (STIs) are on the rise in Africa, causing a slew of health issues and catastrophic difficulties. Sub-Saharan Africa has the greatest annual STD cases as compared to other regions. Each year, 3.5 million incidents of syphilis are reported by the World Health Organization in Africa. STDs are a major public health problem due to their widespread prevalence and treatability. In Sub-Saharan Africa, infections with the herpes virus and the human papillomavirus are becoming more prevalent. While there are over 20 germs that cause STDs, they are most commonly manifested in four syndromes and can thus be addressed syndromic.

The Brazil market dominated the LAMEA Syphilis Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $27.9 million by 2028. The Argentina market is estimated to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 8.1% during (2022 - 2028).

Based on Type, the market is segmented into Primary & Secondary Syphilis and Others. Based on Location of Testing, the market is segmented into Laboratory testing and Point of care (POC) testing. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Syphilis Testing Market is Predict to reach $1.5 Billion by 2028, at a CAGR of 5.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd.

Recent Strategies Deployed in Syphilis Testing Market

  • May-2022: Orthofix Medical received a U.S. Food and Drug Administration for AccelStim bone healing treatment Class III device. The AccelStim device offers an effective and safe nonsurgical therapy for demonstrating fresh fractures and for fractures that have not to cure.
  • Mar-2022: Zimmer Biomet signed an agreement with Biocomposites, an international medical device enterprise. Together the companies aimed to solely administer its Genex bone graft replacement with its new combining system and provide options in the US orthopedic industry. Additionally, genex bone graft substitute tools to surgeons to proceed in business to mitigate enhancement and pain the capacity of life for consumers across the world.
  • Feb-2022: DJO extended its partnership with the Professional Football Athletic Trainers Society, an experienced society composed of authorized athletic coaches working in professional football. Through this partnership, the entities aimed to promote athlete health through schemes such as join the Club, DJO’s precautionary uplifting scheme for high school sportspersons.
  • Sep-2021: DJO, a subsidiary of Colfax Corporation unveiled MedShape DynaNail Hybrid Fusion System. The DynaNail Hybrid adaptive, active healing to deliver cutting-edge, creative automation to patients that would get them back on their feet earlier and keep them effective for longer.
  • Apr-2021: Orthofix Medical signed an agreement to commercialize the innovative suite of IGEA, cartilage, and soft tissue stimulation products in the U.S and Canada. Through this agreement, Orthofix has the right to attempt U.S Food and Drug Administration commercialization and acceptance of IGEA’s policy on orthopedic products, which are not presently accessible in the U.S.
  • Nov-2018: DJO came into a partnership with SirenMD, a technology platform that powers athlete health by connecting the trainers, physicians, and loved ones who treat them. Through this partnership, the companies aimed to address some of the medical carelessness with an integrated telecommunications platform and enhance complete patient healthcare.

Scope of the Study

Market Segments Covered in the Report:

By Type

  • Primary & Secondary Syphilis
  • Others

By Location of Testing

  • Laboratory testing
  • Point of care (POC) testing

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Siemens Healthineers AG
  • Abbott Laboratories
  • DiaSorin S.p.A. (Luminex Corporation)
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Syphilis Testing Market Report 2022-2028

North America Syphilis Testing Market Report 2022-2028

Europe Syphilis Testing Market Report 2022-2028

Asia Pacific Syphilis Testing Market Report 2022-2028

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities